From AbbVie’s upadacitinib to new gene therapies: Pharma’s 2019 blockbuster launches, ranked


The biopharma industry will see seven blockbuster launches this year, according to Clarivate’s annual “Drugs to Watch” list for 2019! See how they rank:

  1. AbbVie’s upadacitinib
  2. Novartis’ Zolgensma
  3. AstraZeneca & FibroGen’s roxadustat
  4. Alexion’s Ultomiris
  5. Boehringer Ingelheim & AbbVie’s Skyrizi
  6. Aimmune’s AR-101
  7. bluebird bio’s LentiGlobin

Read the full article at…


Comments are closed.

More in Ashton Tweed Connection
HIV drugmakers ViiV, Gilead top 2018 pharma reputation survey

According to an annual patient group opinion report from PatientView, 41% thought the pharma industry's reputation was “excellent” or “good”...